Acrux Pharmaceuticals News and Activities

Acrux Pharmaceuticals is a company listed under the stock ticker ACXP (US).

View the org chart displaying its 9 main executives

Most searched biographies at Acrux Pharmaceuticals

• David Luci, President and Chief Executive Officer
• Jack Dean, Director
• Robert DeLuccia, Executive Chairman of the Board

Create your alert
to follow the executive moves at Acrux Pharmaceuticals.

Acrux Pharmaceuticals has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Acrux Pharmaceuticals

• Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
• Press Releases
• Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
• Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
• Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
• Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
• Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
• Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
• View more press releases Close

Social media about Acrux Pharmaceuticals

• Acrux Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acrux Pharmaceuticals on LinkedIn, X (Twitter) & YouTube